Skip to content

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06388304
Acronym
THRIVE
Enrollment
39
Registered
2024-04-29
Start date
2024-03-12
Completion date
2025-04-18
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, DCIS

Brief summary

The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.

Interventions

BEHAVIORALTHRIVE Online PAT Program

Online program: behavioral intervention based on Positive Affect Training (PAT)

Sponsors

Joanna Arch
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* hormone receptor-positive breast cancer stages 0-3 * have finished primary treatment (chemotherapy/radiation/surgery) * are prescribed endocrine therapy (ET) currently or within the last two years * score above specified cut off (range, 0-10) on any of three questions: 1. How upset are you by having to take anti-hormonal therapy 2. How bothered are you by the side effects? 3. How difficult is it for you to take your anti-hormonal medication every day? * have internet access to complete online assessments and intervention components or agree to use and return a study wifi-activated iPad.

Exclusion criteria

* metastatic disease * Individuals who are unable to interact with the intervention as needed. This includes those who are extremely visually impaired to the degree that they cannot see the screen and interact as required and individuals who cannot read and/or write in English. This is due to the nature of the intervention itself. If a participant is unable to interact with THRIVE as required, they are unlikely to benefit from the intervention or offer insightful feedback that can be used in refining the program.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability of THRIVE intervention (AIM)1 week post-interventionAcceptability of Implementation Measure (Weimer et al., 2017)
Feasibility of THRIVE intervention1 week post-interventionFeasibility of Intervention Measure (Weimer et al., 2017)
Client Satisfaction Survey1 week post-interventionSatisfaction and feedback on THRIVE intervention

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoanna Arch, PhD

University of Colorado, Boulder

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026